Abstract |
1. The effects of pimozide on the psychopathology of delusional disorder were studied. 2. After six weeks, pimozide (2-12 mg/day) administration had no effect on the Brief Psychiatric Rating Scale, or in the psychological, social and occupational functioning, as measured by the Global Assessment of Functioning Scale. 3. When the different dimensions of the delusional experience were looked upon, no modifications were observed in any of them after six weeks of pimozide treatment. 4. These data failed to support the therapeutic role of pimozide in the treatment of delusional disorder and may suggest, when compared to other disorders with prominent delusions such as schizophrenia, a different neurobiology for the illness.
|
Authors | H Silva, S Jerez, A Ramirez, P Renteria, N Aravena, D Salazar, R Labarca |
Journal | Progress in neuro-psychopharmacology & biological psychiatry
(Prog Neuropsychopharmacol Biol Psychiatry)
Vol. 22
Issue 2
Pg. 331-40
(Feb 1998)
ISSN: 0278-5846 [Print] England |
PMID | 9608605
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antipsychotic Agents
- Pimozide
|
Topics |
- Adult
- Antipsychotic Agents
(pharmacology, therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Pimozide
(pharmacology, therapeutic use)
- Psychiatric Status Rating Scales
- Schizophrenia, Paranoid
(drug therapy)
- Treatment Outcome
|